Could carbon monoxide and bilirubin be friends as well as foes of the body?

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 70, Issue 1, 2010, Pages 1-5

  Breimer, Lars H ^a   Mikhailidis, Dimitri P ^b  

^a ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bilirubin; Carbon monoxide; CO RMs; Reactive oxygen species; Signalling; Vascular disease

Indexed keywords

ALPHA 2 ANTIPLASMIN; BILIRUBIN; BIOLOGICAL MARKER; CARBON MONOXIDE; CARBOXYHEMOGLOBIN; GUANYLATE CYCLASE INHIBITOR; HEAT SHOCK PROTEIN 32; HEME OXYGENASE 1; HEME OXYGENASE 2; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; NITRIC OXIDE; PLACEBO; POTASSIUM CHANNEL BLOCKING AGENT; REACTIVE OXYGEN METABOLITE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ALLOTRANSPLANTATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA THROMBOSIS; ARTERY THROMBOSIS; BILIRUBIN BLOOD LEVEL; CARBON MONOXIDE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL PROTECTION; CORONARY ARTERY DISEASE; DRUG TARGETING; ENZYME ACTIVATION; HEART MUSCLE PERFUSION; HEART PROTECTION; HUMAN; IMMUNITY; IMMUNOMODULATION; KIDNEY FUNCTION; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN FUNCTION; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; VASCULAR DISEASE; VASODILATATION;

ANIMALS; BILIRUBIN; BILIVERDINE; CARBON MONOXIDE; CARBON MONOXIDE POISONING; HUMANS; NITRIC OXIDE;

ANIMALIA;

EID: 76749128913     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365510903494252     Document Type: Review

References (49)

1. Sjöstrand T. Endogenous production of carbon monoxide in man under normal and pathophysiological conditions. Scand J Clin Lab Invest 1949;1:201-214
2. Sjöstrand T. The formation of carbon monoxide by the decomposition of hemoglobin in vivo. Acta Physiol Scand 1952;26:338-344
3. Ryter SW, Alam J, Choi AMK. Heme oxygenase-1/carbon monoxide: From basic science to therapeutic applications. Physiol Rev 2006;86:583-650.
4. Foresti R, Green CJ, Motterlini R. Generation of bile pigments by haem oxygenase: a refined cellular strategy in response to stressful insults. Biochem Soc Symp 2004;71:177-192
5. Otterbein LE. Carbon monoxide: innovative anti-inflammatory properties of an age-old gas molecule. Antioxid Redox Signal 2002;4:309-319
6. Motterlini R, Mann BE, Foresti R. Therapeutic applications of carbon monoxide-releasing molecules. Expert Opin Investig Drugs 2005;14:1305-1318
7. Öllinger R, Wang HJ, Yamashita K, Wegiel B, Thomas M, Margreiter R, Bach FH. Therapeutic applications of bilirubin and biliverdin in transplantation. Antioxid Redox Signal 2007;9:2175-2185
8. Foresti B, Bani-Hani MG, Motterlini R. Use of carbon monoxide as a therapeutic agent: promises and challenges. Intensive Care Med 2008;34:649-658
9. Stocker R, Ames BN. Potential role of conjugated bilirubin and copper in the metabolism of lipid peroxides in bile. Proc Natl Acad Sci USA 1987;84:8130-8134
10. Sedlak TW, Snyder SH. Bilirubin benefits: cellular protection by a biliverdin reductase antioxidant cycle. Pediatrics 2004;113:1776-1782
11. Gorman D, Drewry A, Huang YL, Sames C. The clinical toxicology of carbon monoxide. Toxicology 2003;187:25-38.
12. Scharte M, von Ostrowski TA, Daudel F, Freise H, Van Aken H, Bone HG. Endogenous carbon monoxide production correlates weakly with severity of acute illness. Eur J Anaesthesiol 2006;23:117-122
13. Otterbein L E, Bach FH, Alam J, Soares M, Tao Lu H, Wysk M, Davis RJ, Flavell RA, Choi AM. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Med 2000;6:422-428
14. Tsui TY, Obed A, Siu YT, Yet SF, Prantl L, Schlitt HJ, Fan ST. Carbon monoxide inhalation rescues mice from fulminant hepatitis through improving hepatic energy metabolism. Shock 2007;27:165-171
15. Mayr FB, Spiel A, Leitner J, Marsik C, Germann P, Ullrich R, Wagner O, Jilma B. Effects of carbon monoxide inhalation during experimental endotoxemia in humans. Am J Respir Crit Care Med 2005;171:354-360
16. Sarady JK, Zuckerbraun BS, Bilban M, Wagner O, Usheva A, Liu F, Ifedigbo E, Zamora R, Choi AM, Otterbein LE. Carbon monoxide protection against endotoxic shock involves reciprocal effects on iNOS in the lung and liver. FASEB J 2004;18:854-856
17. Johnson FK, Johnson RA. Carbon monoxide promotes endotheliumdependent constriction of isolated gracilis muscle arterioles. Am J Physiol Regul Integr Comp Physiol 2003;285:R536-41.
18. Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, Schröder H. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med 2003;228:529-534
19. Serhan CN, Takano T, Maddox JF. Aspirin-triggered 15-epilipoxin A4 and stable analogs on lipoxin A4 are potent inhibitors of acute inflammation: receptors and pathways. Adv Exp Med Biol 1999;447:133-149
20. Weid P-Y, Hollenberg MD, Fiorucci S, Wallace JL. Aspirintriggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation 2004;110:1320-1325
21. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, Villela CG, Fierro IM. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 2005;289:C557-63.
22. Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994;40:18-23.
23. Breimer LH, Spyropolous KA, Winder AF, Mikhailidis DP, Hamilton G. Is bilirubin protective against coronary artery disease? Clin Chem 1994;40:1987-1988
24. Breimer LH, Wannamethee G, Ebrahim S, Shaper, AG. (1995). Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995;41:1504-1508
25. Breimer LH, Mikhailidis DP. Bilirubin and peripheral arterial disease: 15 years later. Expert Opin Ther Targets 2009;13:139-140
26. Breimer LH. Bilirubin and cardiovascular disease. J Insur Med in press.
27. Fulks M, Stout RL, Dolan VF. Mortality associated with bilirubin levels in insurance applicants. J Insur Med 2009;41:49-53.
28. Adin CA, Croker BP, Agarwal A. Protective effects of exogenous bilirubin on ischemia-reperfusion injury in the isolated, perfused rat kidney. Am J Physiol Renal Physiol 2005;288:F778-84.
29. Kirkby K, Baylis C, Agarwal A, Croker B, Archer L, Adin C. Intravenous bilirubin provides incomplete protection against renal ischemia-reperfusion injury in vivo. Am J Physiol Renal Physiol 2007;292:888-894
30. Ceran C, Sonmez K, Turkyllmaz Z, Demirogullarl B, Dursun A, Duzgun E, Basaklar AC, and Kale N. Effect of bilirubin in ischemia/reperfusion injury on rat small intestine. J Pediatr Surg 2001;36:1764-1767
31. Demirogullari B, Ekingen G, Guz G, Bukan N, Edam O, Ozen IO, Memis L, Sert S. A comparative study of the effects of hemin and bilirubin on bilateral renal ischemia reperfusion injury. Nephron Exp Nephrol 2006;103:e1-5.
32. Attuwaybi BO, Kozar RA, Moore-Olufemi S D, Sato N, Hassoun HT, Weisbrodt NW, Moore FA. Heme oxygenase-1 induction by hemin protects against gut ischemia/ reperfusion injury. J Surg Res 2004;118:53-57
33. Oberle S, Abate A, Grosser N, Hemmerle A, Vreman HJ, Dennery PA, Schneider HT, Stalleicken D, Schröder H. Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators. Exp Biol Med 2003;228:529-534
34. Sayed N, Baskaran P, Ma X, Akker F, Beuve A. Desensitization of soluble guanyl cyclase, the NO receptor, by Snitrosylation. Proc Natl Acad Sci USA 2007;104:12312-12317
35. Chang F-J, Lemme S, Sun Q, Sunhara RK, Beuve A. Nitric oxide-dependent allosteric inhibitiory role of a second nucleotide binding site in soluble guanylyl cyclase. J Biol Chem 2005;280:11513-11519
36. Grosser N, Hemmerle A, Berndt G, Erdmann K, Hinkelmann U, Schurgerc S, Wijayanti N, Immenschuh S, Schroder H. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med 2004;37:2064-2071
37. Gueler F, Park J-K, Rong S, Kirsch T, Lindschau C, Zheung W, Elger M, Fiebeler A, Fliser D, Luft FC, Haller H. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infi ltrating macrophages. Am J Pathol 2007;170:1192-1199
38. Muchova L, Wong RJ, Hsu M, Morioka I, Vitek L, Zelenka J, Schröder H, Stevenson DK. Statin treatment increases formation of carbon monoxide and bilirubin in mice: a novel mechanism of in vivo antioxidant protection. Can J Physiol Pharmacol 2007;85:800-810
39. Desbuards N, Rochefort GY, Schlecht D, Machet MC, Halimi JM, Eder V, Hyvelin JM, Antier D. Heme oxygenase-1 inducer hemin prevents vascular thrombosis. Thromb Haemost 2007;98:614-620
40. Wang H, Lee SS, Dell'Agnello C, Tchipashvili V, d'Avila JC, Czismadia E, Chin BY, and Bach FH. Bilirubin can induce tolerance to islet allografts. Endocrinology 2006;147: 762-768
41. Sato K, Balla J, Otterbein L, Smith RN, Brouard S, Lin Y, Csizmadia E, Sevigny J, Robson SC, Vercellotti G, Choi AM, Bach FH, Soares MP. Carbon monoxide generated by heme oxygenase-1 suppresses the rejection of mouseto- rat cardiac transplants. J Immunol 2001;166:4185-4194
42. Marazioti A, Baskaran P, Beuve A, Romao C, Pyriochou A, Papapetropoulos A. Effects of carbon monoxide-releasing molecules on cGMP levels and soluble guanylate cyclase activity. BMC Pharmacology 2009;9(Suppl. 1):P45 DOI:10.1186/1471-2210-9-S1-P45.
43. Chen B, Guo L, Fan C, Bolisetty S, Joseph R, Wright MM, Agarwal A, George JF. Carbon monoxide rescues heme oxygenase-1-deficient mice from arterial thrombosis in allogeneic aortic transplantation. Am J Pathol 2009;175:422-429
44. Nielsen VG, Kirklin JK, George JF. Carbon monoxide releasing molecule-2 increases the velocity of thrombus growth and strength in human plasma. Blood Coagul Fibrinolysis 2009;20:377-380
45. Chlopicki S, Olszanecki R, Marcinkiewicz E, Lomnicka M, Motterlini R. Carbon monoxide released by CORM-3 inhibits human platelets by a mechanism independent of soluble guanylate cyclase. Cardiovasc Res 2006;71:393-401.
46. Motterlini R, Sawle P, Hammad J, Bains S, Alberto R, Foresti R, Green CJ. CORM-A1: a new pharmacologically active carbon monoxide-releasing molecule. FASEB J 2005;19:284-286
47. Sandouka A, Fuller BJ, Mann BE, Green CJ, Foresti R, Motterlini R. Treatment with carbon monoxide-releasing molecules (CO-RMs) during cold storage improves renal function at reperfusion. Kidney Int 2006;69:239-247
48. Varadi H, Lekli I, Juhasz B, Bacskay I, Szabo G, Gesztelyi R, Szendrei L, Varga E, Bak I, Foresti R, Motterlini R, Tosaki A.Beneficial effects of carbon monoxidereleasing molecules on post-ischemic myocardial recovery. Life Sci 2007;80:1619-1626
49. Ramshorst J, Bax JJ, Beeres SLMA, Dibbets-Schneider P, Roes SD, Stokkel MPM, de Roos A, Fibbe WE, Zwaginga JJ, Boersma E, Schalij MJ, Atsma DE. Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA 2009;301:1997-2004.